SABS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SAB Biotherapeutics Inc (SABS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline, the financial performance is weak, hedge funds are selling, and there are no strong trading signals or immediate catalysts to justify an entry at this time.
The technical indicators show mixed signals. The MACD is slightly positive, but RSI is neutral at 43.688. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 3.88, with key resistance at 4.032 and support at 3.727. The stock's short-term trend suggests a 60% chance of a slight decline (-1.47%) in the next day and a minor gain (0.83%) in the next week.
Analysts have given a Buy rating with a significant upside potential (price target of $13-$14).
Promising developments in SAB-142 for Type 1 diabetes, with new clinical findings presented recently.
Hedge funds are aggressively selling, with a 10058566.67% increase in selling activity last quarter.
Weak financial performance, including a 100% YoY revenue drop and negative EPS.
No recent insider or congress trading activity to indicate confidence.
Options data shows a high put-call ratio, indicating bearish sentiment.
The company's financials for Q4 2025 are weak, with revenue dropping to $0 (-100% YoY), net income down to -$2,845,412 (-75.03% YoY), and EPS falling to -0.06 (-95.12% YoY). Gross margin also dropped to 0 (-100% YoY), indicating significant financial challenges.
Analysts are optimistic about the long-term potential of SAB Biotherapeutics, with Buy ratings and price targets of $13-$14. However, the key catalyst (data from SAB-142 trials) is expected in the second half of 2027, which is a long-term horizon.
